Lixisenatide (Lyxumia®) approved in Europe for adults with type 2 diabetes mellitus

Source: BioSpace Area: News According to BioSpace, the European Commission has granted Marketing Authorisation in Europe for lixisenatide (Lyxumia®) for the treatment of adults with type 2 diabetes mellitus, to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.   Lixisenatide is the first once-daily prandial glucagon-like peptide-1 receptor agonist to be approved in Europe. The approval was based on results from the GetGoal clinical programme, which included 11 clinical trials involving more than 5,000 patients with type 2 diabetes.   NICE recently published a new medicines evidence summary on lixisenatide - please see the link below for information.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news